Obesity is a serious concern not only known to risk heart health but several other metabolic diseases are connected to obesity. Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, resulted in greater weight loss, according to a recent study published in the JAMA.
Earlier Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. Therefore a randomized controlled trial was conducted to compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity.
For more information check out the full story on the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)